Abstract 166P
Background
Genomic tests designed to facilitate decisions about treatment management include those that identify alterations in single genes and multimarker tumor panels. Multimarker panels include targeted gene-expression profiling tests that are used to estimate prognosis and/or the likelihood of recurrence. Currently, there are no nationally representative data describing oncologists’ awareness, knowledge, and use of NGS testing to inform patient care, especially in community practice settings. The purpose of this study was to investigate how oncologists in the Pakistan use NGS tests to evaluate patients with cancer and inform treatment recommendations.
Methods
This study was performed retrospectively on 73 biopsy specimens received for histopathological workup at the Aga Khan University Hospital. The specimens were obtained between January 2021 and December 2022. The diagnosis of malignancy was confirmed based on histpathochemical features. Briefly, DNA from FFPE tissues were extracted and tested through TruSight Tumor 15 (TST15) targeted cancer gene panel to detect variants in 15 genes associated with solid tumors using High throughput DNA sequencing; next-generation sequencing (NGS) technology to sequence DNA on Illumina, Miseq Insturment.
Results
Out of 73 patients tested, 28 (38.3%) were females and 45 (61.6%) were males with a median age of 52 years and patients’ ages ranged from 20 years to 84 years. The histopathological diagnosis were inclusive of 7 cancer types (Lung, Melanoma, Breast, Colon, Ovarian, Gastric, and Prostate. All samples underwent targeted analysis of tumor mutations to check for the presence of somatic gene variants. The outcome demonstrated no mutation in 14 (19.17%) patients, whereas, 59 (80.8%) tested positive with mutations in 7 of the 15 targeted genes such as TP53 (54.7%), KRAS (27%), EGFR (12%), PIK3CA (10.9%), ERBB2 OR HER2 (5.5%), NRAS (4%), MET (1%) and BRAF (1%).
Conclusions
NGS testing is changing the paradigm for molecular testing in these patients, with time, it should be possible to apply NGS to routine diagnostics. More research is needed to establish the clinical usefulness of these tests, to develop evidence-based clinical guidelines for their use in practice.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract